The BIO CITY is a hub of biotechnologies, where cutting-edge tech meets boundless ideas to shape the future and redefine what’s possible. Here, science, technology and creativity converge to fuel a shared mission – a future where we will live longer, healthier and more fulfilled lives. When we talk about the future, we don’t just see challenges – we see endless opportunities. Because throughout time, the most precious asset will remain forever unchanged – life itself.
Northway Group is embarking on a project to establish Europe’s largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania.
In Vilnius, Lithuania, a pivotal moment was marked with the first topping-out ceremony at the BIO CITY complex, a project developed by the Northway Healthcare Group.
BIO CITY is poised to launch the premier Gene Therapy Centre in the Baltic States, dedicated to contract development and the manufacturing of gene therapies. Catering to an estimated 280 million individuals globally who are facing rare genetic diseases, our state-of-the-art facility will focus on both advanced research and the production of solutions. By establishing this centre, we aim to introduce 100 specialised roles in the CDMO sector. This initiative underscores our commitment to be leaders of the industry and to actualise a transformative vision.
The R&D and Virology Centre at BIO CITY is exclusively devoted to the advancement of gene therapy research. As an integral part of our CDMO services, this centre will harness cutting-edge technologies and methodologies, to pioneer innovative solutions in the gene therapy domain. Our commitment is to bridge the gap between complex research and practical applications, providing our partners with unparalleled expertise and capabilities in gene therapy development.
Our Life Science Industry Hub will serve as a beacon for integrating intelligent solutions into biotechnological research. The aim of the hub is to foster a collaborative environment where innovation, technology and life sciences intersect, ensuring that research is not only cutting-edge but also accessible and transformative for the industry as a whole.
Specialising in contract development and the manufacturing of stem cell therapies, the Stem Cell and 3D Bioprinting Centre promises to be a beacon of innovation. The facility will offer specialised services for the identification, characterisation and expansion of isolated primary stem cell populations. With our cutting-edge automated bioreactor systems, we aim to provide therapeutic applications, thereby reinforcing our commitment to excellence in the industry.
BIO CITY’s Large-Scale Microbial Production Centre is the epitome of excellence in the contract manufacturing of microbial proteins. Designed to meet the rigorous demands of the industry, the facility will be equipped with advanced tools, including Stainless Steel Bioreactors and Industrial Chromatographic systems, to ensure an unparalleled product quality and compliance with the standards.
Our Large-Scale Mammalian Production Centre signifies a leap forward in the CDMO sector’s approach to the contract development and manufacturing of therapeutic monoclonal antibodies. With a focus on diseases like cancer, asthma and other inflammatory conditions, the facility will harness the most sophisticated technologies, ensuring optimal protein purification and manufacturing.
1
2024
3
2027
2
2026
4
2028
5
2029
6
2030
1
2024
2
2026
3
2027
4
2028
5
2029
6
2030
